Antidepressant withdrawal and discontinuation

What discontinuation feels like

The classic acronym is FINISH: Flu-like symptoms, Insomnia, Nausea, Imbalance, Sensory disturbances, Hyperarousal.

• Flu-like: aches, fatigue, sweating, chills, headache.
• Insomnia and vivid dreams.
• Nausea, sometimes with vomiting or diarrhea.
• Dizziness or imbalance, sometimes described as "rocking on a boat."
• Sensory disturbances: the most distinctive symptom is "brain zaps," brief electric-shock sensations in the head, often triggered by eye movements.
• Hyperarousal: anxiety, irritability, agitation, sometimes tearfulness.

Symptoms typically begin within two to four days of a missed dose or a dose reduction and resolve within one to two weeks for most people. Severity varies widely.

Why it happens

Antidepressants change the activity of serotonin, norepinephrine, and other systems over weeks. The brain adapts. When the medication is stopped abruptly, the adapted state takes time to readjust. The longer the medication has been taken and the shorter its half-life, the more pronounced this readjustment tends to be.

This is not addiction. People do not crave antidepressants, do not escalate doses to get the same effect, and do not experience the compulsive use patterns that define addiction. Discontinuation symptoms are a physiological adjustment, not a behavioral disorder.

Risk by medication

The risk of significant discontinuation symptoms is highest for medications with short half-lives and strongest for medications with cholinergic activity.

• Highest risk: paroxetine (Paxil), venlafaxine (Effexor), and desvenlafaxine (Pristiq). Half-lives are short and symptoms can begin within 24 to 48 hours of a missed dose.
• Moderate risk: sertraline, citalopram, escitalopram, duloxetine, vortioxetine.
• Lowest risk: fluoxetine (Prozac). Its long half-life (about 4 to 6 days for the parent drug, longer for the active metabolite) means the body tapers itself.
• Bupropion rarely produces classic discontinuation symptoms.
• Tricyclics can produce gastrointestinal and cholinergic rebound symptoms.
• MAOIs can produce delirium and agitation if stopped abruptly.

How to taper

The traditional advice was to halve the dose every one to two weeks. The current evidence, summarized by Horowitz and Taylor in Lancet Psychiatry (2019, 2022) and adopted in the 2024 Royal College of Psychiatrists guidance, supports much slower, hyperbolic tapers, especially after long use.

• Short-term use (under six months): a taper over two to four weeks is usually adequate.
• Longer-term use (more than a year): a taper over months is often better tolerated. Reducing by smaller and smaller absolute amounts (for example, 25 percent of the current dose every two to four weeks rather than 25 percent of the original dose) matches the curve of receptor occupancy and reduces the chance of severe symptoms.
• If symptoms appear, hold the dose and let symptoms settle before reducing further. Going back up to the previous dose for one to two weeks is sometimes necessary.
• Liquid formulations and compounded smaller doses make small reductions possible. Pharmacists who compound psychiatric medications can prepare doses below the smallest commercial tablet.
• Switching to fluoxetine before tapering (a "Prozac bridge") is a long-standing strategy for difficult tapers from short-half-life agents like paroxetine or venlafaxine.

Tapering should be done with the prescriber, not alone. The prescriber can help distinguish between withdrawal and a returning depressive episode, which look similar in the first weeks but require different responses.

Withdrawal versus relapse

This is the question that most often confuses patients and prescribers.

• Timing. Withdrawal usually starts within days. Relapse usually takes weeks to months to develop.
• Quality of symptoms. Brain zaps, dizziness, flu-like aches, and nausea are not symptoms of depression. They are withdrawal.
• Response to a small dose. Withdrawal symptoms usually improve within 24 to 72 hours of resuming the previous dose. A returning depressive episode does not.
• Course. Withdrawal symptoms typically improve over one to two weeks even if no medication is restarted. Depressive symptoms typically do not.

Persistent post-withdrawal symptoms

A minority of patients experience symptoms lasting weeks to months after stopping, sometimes called persistent post-withdrawal syndrome or protracted antidepressant withdrawal. The symptoms can include lingering brain zaps, sensory disturbances, autonomic instability, sexual side effects, and emotional lability.

The condition is real, the literature is still developing, and there is no specific treatment beyond patience, slower tapering if any active dose remains, and supportive care. Reinstating a small dose and tapering more slowly resolves the symptoms in some patients. The phenomenon is more common after long use of paroxetine, venlafaxine, and high-dose SNRIs, and after rapid tapers.

When stopping is not the right move

For people with a single depressive episode that has been in remission for at least six to twelve months, stopping with a slow taper is reasonable. For people with two or more episodes, with chronic depression, or with a history of severe episodes (psychosis, suicidality, hospitalization), guidelines support continued maintenance treatment, often for two years or longer. The relapse rate after stopping in this group is high.

The decision to stop is best made when you are stable, when life stress is manageable, and with a plan for what to do if symptoms return.